Casi Phrmactcls Inc (NASDAQ:CASI) is at $3.35 seeing a daily low of $3.05 and a high of $3.57. The swing classifies the stock as one of the day’s most volatile.
It is one of the market’s biggest gainers today.
Short traders are more bearish on shares of the company if you consider the change in short interest. The firm saw a rise in short interest of 260.18% as of October 13, 2017 from the last reporting period. Short shares increased from 113,739 to 409,668 over that period. The days to cover decreased to 0.0 and the percentage of shorted shares is 0.01% as of October 13.
Recent Analyst Ratings
On September 8 Maxim Group kept the company rating at “Buy” projecting a price of $4.00. September 8 investment analysts at HC Wainwright kept the stock rating at “Buy” targeting a price of $2.00.
On August 14, 2017 Maxim Group released guidance on CASI and giving a rating of “Buy” and setting a price target of $4.00.
Earnings Per Share
The most current P/E ratio is N/A and the market cap is 217.97M. In the last earnings report the EPS was $-0.12 with 65.07M shares presently outstanding.
CASI Pharmaceuticals, Inc., launched on September 18, 1991, is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. The Company operates through the development of targeted therapeutics primarily for the treatment of cancer segment. The Business’s product pipeline includes internal development of its lead drug candidate, ENMD-2076; MARQIBO, ZEVALIN and EVOMELA, the United States Food and Drug Administration (FDA) approved drugs in-licensed from Spectrum Pharmaceuticals, Inc., and early-stage candidates in preclinical development. The Business’s pipeline also includes 2ME2 (2-methoxyestradial). The Business’s primary research and development focuses on oncology therapeutics..